What is the recommended protocol for transitioning a patient from methotrexate to adalimumab (Humira)?

Transitioning from Methotrexate to Adalimumab (Humira)

You can add adalimumab directly to methotrexate without a washout period or tapering—methotrexate should typically be continued alongside adalimumab rather than discontinued, as combination therapy is more effective than switching to adalimumab monotherapy.

Recommended Transition Protocol

Immediate Addition (Preferred Approach)

• Start adalimumab 40 mg subcutaneously every other week while maintaining current methotrexate dose 1
• No washout period is required—evidence demonstrates that switching to a second biologic without a washout period after unsuccessful primary treatment is both effective and safe 2
• Continue methotrexate at the current therapeutic dose (typically 15-25 mg weekly) 3

Why Continue Methotrexate?

The evidence strongly supports combination therapy over monotherapy:

• Adalimumab plus methotrexate achieves significantly higher response rates than adalimumab alone 4, 5
• In psoriatic arthritis, 41% of patients achieved minimal disease activity with adalimumab plus methotrexate versus only 13% with methotrexate escalation alone 4
• Combination therapy reduces antidrug antibody formation, which can compromise adalimumab effectiveness 6
• The FDA label explicitly states that methotrexate and other non-biologic DMARDs may be continued during adalimumab treatment 1

Loading Dose Considerations

For certain conditions requiring more aggressive initial control, consider a loading dose strategy:

• Crohn's disease/Ulcerative colitis: 160 mg Day 1, then 80 mg at Week 2, then 40 mg every other week starting Week 4 1
• Hidradenitis suppurativa: 160 mg Day 1, then 80 mg at Week 2, then 40 mg weekly or 80 mg every other week starting Week 4 1
• Rheumatoid arthritis/Psoriatic arthritis: Standard 40 mg every other week (no loading dose typically needed) 1

Key Clinical Pitfalls to Avoid

Do NOT Discontinue Methotrexate Prematurely

• Common mistake: Stopping methotrexate when starting adalimumab
• Why this matters: Methotrexate reduces immunogenicity against adalimumab and enhances clinical response 5, 7
• Exception: Only discontinue methotrexate if there are specific contraindications or intolerance

Do NOT Taper Methotrexate During Transition

• Maintain the current therapeutic dose
• If methotrexate was suboptimal at ≤15 mg weekly, you could escalate to 20-25 mg weekly while adding adalimumab, though adding adalimumab is more effective than methotrexate escalation alone 4

Do NOT Use a Washout Period

• Immediate transition is safe and prevents disease flare
• One study showed immediate transition from etanercept, methotrexate, or phototherapy to adalimumab had low risk of disease flare (only 2.6% experienced ≥125% worsening) 8

Monitoring Requirements

Before initiating adalimumab:

• Screen for latent tuberculosis (required by FDA) 1
• Assess for active infections
• Update hepatitis B screening

During transition:

• Monitor disease activity at 4-8 weeks to assess early response 9
• Baseline disease activity and early response (within 12 weeks) predict long-term outcomes 9
• If inadequate response by 12-16 weeks, consider dose escalation to 40 mg weekly 1

When to Consider Adalimumab Monotherapy

Adalimumab monotherapy is only appropriate when:

• Methotrexate is contraindicated (e.g., significant hepatotoxicity, severe cytopenias)
• Patient has documented methotrexate intolerance despite optimization strategies (subcutaneous route, split dosing, increased folate) 3
• Patient has rheumatoid arthritis with interstitial lung disease (avoid methotrexate in this scenario) 2

Even in monotherapy, some patients may benefit from dose escalation to 40 mg weekly if response is suboptimal 1.

Special Populations

Pediatric patients (JIA-associated uveitis): Strong evidence supports initiating and continuing adalimumab with methotrexate, which markedly reduces relapse risk (HR 0.18) 7

Elderly patients (≥65 years): No dose adjustment needed, but heightened monitoring for infections is warranted 1

Bottom Line Algorithm

1. Screen for TB and infections before starting adalimumab
2. Continue current methotrexate dose (do not taper or discontinue)
3. Add adalimumab 40 mg subcutaneously every other week (no washout period)
4. Assess response at 8-12 weeks—if suboptimal, escalate adalimumab to weekly dosing
5. Only discontinue methotrexate if specific contraindications develop

This approach maximizes efficacy while maintaining safety, supported by both FDA labeling 1 and current rheumatology guidelines 2, 3.